Xeris Biopharma Holdings, Inc. XERS revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Xeris Biopharma Holdings, Inc. reported revenue across 6 products and services; the largest, Product, was $283M (+43.9% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$283Mshare n/a+43.9% yoy
- Recorlev$139Mshare n/a+116.7% yoy
- Gvoke$94.1Mshare n/a+13.6% yoy
- Keveyis$47.6Mshare n/a-3.8% yoy
- Royalty Contract And Other Revenue$8.84Mshare n/a+37.4% yoy
- Product Other$1.96Mshare n/ano prior
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Product$82.5Mshare n/a+42.6% yoy
- Recorlev$49.8Mshare n/a+94.9% yoy
- Gvoke$20.8Mshare n/a-0.2% yoy
- Keveyis$11.9Mshare n/a+4.0% yoy
- Royalty Contract And Other Revenue$673Kshare n/a-71.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.